## IDXX: IDEXX Laboratories, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.4% below STRENGTH zone (3.0-6.0%); PEG 4.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($666.52)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Riverbridge Partners LLC Reduces Holdings in IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251222T125432 | Neutral | Relevance: 100%
- Riverbridge Partners LLC has reduced its stake in IDEXX Laboratories, Inc. ($IDXX) by 3.9% in Q3, selling 3,897 shares and now holding 95,433 shares valued at approximately $60.97 million. Concurrently, IDEXX EVP Nimrata Hunt sold 9,425 shares for about $6.63 million, decreasing her position by 30.83%. Despite these sales, analysts generally maintain a "Moderate Buy" rating with a consensus target price of $763.50, following strong Q3 earnings and positive FY2025 guidance.

**2. IDEXX Laboratories, Inc. $IDXX Shares Sold by Seilern Investment Management Ltd**
- Source: MarketBeat | 20251222T110838 | Bullish | Relevance: 100%
- Seilern Investment Management Ltd significantly reduced its stake in IDEXX Laboratories (NASDAQ:IDXX) by 33.4% in the third quarter, selling 70,900 shares, though it remains a top-five holding in their portfolio. Concurrently, IDEXX EVP Nimrata Hunt sold 9,425 shares for approximately $6.63 million, decreasing her ownership by 30.83%. Despite these sales, analysts generally maintain a "Moderate Buy" rating for IDEXX, with a consensus price target of $763.50, following the company's strong Q3 earnings and positive FY2025 guidance.

**3. 3,727 Shares in IDEXX Laboratories, Inc. $IDXX Acquired by USA Financial Formulas**
- Source: MarketBeat | 20251221T131203 | Bullish | Relevance: 100%
- USA Financial Formulas recently acquired 3,727 shares of IDEXX Laboratories, valued at approximately $2.38 million, making it their 22nd largest holding. This comes as IDEXX Laboratories reported strong Q3 earnings, beating analyst estimates for EPS and revenue, and issued positive FY2025 EPS guidance. Despite an EVP's significant share sale, institutional investors maintain a substantial stake in the company, which also holds a "Moderate Buy" consensus analyst rating.

**4. IDEXX Laboratories, Inc. $IDXX Shares Acquired by Franklin Street Advisors Inc. NC**
- Source: MarketBeat | 20251220T110759 | Bullish | Relevance: 100%
- Franklin Street Advisors Inc. NC increased its stake in IDEXX Laboratories, Inc. (IDXX) by 4.5% in the third quarter, bringing its total holdings to 36,714 shares valued at $23.46 million. This makes IDEXX the firm's 28th largest position, accounting for approximately 1.4% of its portfolio. The article also notes that analysts have a "Moderate Buy" consensus rating with an average target price of $763.50, and IDEXX recently beat Q3 earnings expectations.

**5. Veterinary Medicine Market Size to Hit USD 98.51 Billion by 2033, Growing at a CAGR of 8.11% - SNS Insider**
- Source: GlobeNewswire | 20251220T040000 | Somewhat-Bullish | Relevance: 60%
- The global veterinary medicine market is projected to reach USD 98.51 billion by 2033, growing at an 8.11% CAGR from 2026, driven by factors like increasing pet adoption, rising prevalence of zoonotic diseases, and growing demand for preventive animal healthcare. Key drivers also include technological advancements in diagnostics, government initiatives, and the rise of online veterinary pharmacies. North America currently dominates the market, while Asia Pacific is expected to exhibit the fastest growth.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $850 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($2.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.9%)
- Blackrock Inc.: 10.3% (-2.0%)
- State Street Corpora: 4.4% (-1.0%)
- Fundsmith LLP: 3.3% (-1.1%)
- Geode Capital Manage: 3.1% (+1.4%)

### Key Risks

1. Valuation stretched: PEG 4.1x requires aggressive growth execution.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.12 signals overvaluation risk, limited margin of safety. Forward P/E 48.7x stretched relative to 12% growth. Quality metrics strong (ROE 65%, ROA 24%, margin 25%). Insider buying signal ($2.1M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $56.2B |
| Beta | 1.67 |
| 52W Range | $356.14 - $769.98 |
| Short Interest | 3.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.12 |
| Forward P/E | 48.7 |
| Current P/E | 54.4 |
| YoY Growth | 11.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -0.4% (minimal 5-day change). Below STRENGTH zone by 3.4pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.22x) but short-term weakness (below SMA20). MACD histogram bearish (-3.75), momentum weakening. RSI neutral at 49. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.44% (CS: 43) | Neutral |
| RSI_14 | 49.4 | Neutral |
| MACD Histogram | -3.75 | Bearish |
| vs SMA20 | 0.978x | Below |
| vs SMA50 | 1.019x | Above |
| vs SMA200 | 1.224x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $702.12
- **Stop Loss:** $666.52 (5.1% risk)
- **Target:** $737.72 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 33
- **Position Value:** $23,169.96
- **Portfolio %:** 23.17%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-03 (Est: $2.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.14 | $3.40 | +8.3% |
| 2025Q2 | $3.30 | $3.63 | +10.0% |
| 2025Q1 | $2.85 | $2.96 | +3.9% |
| 2024Q4 | $2.40 | $2.62 | +9.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*